1,183
Views
0
CrossRef citations to date
0
Altmetric
Oncology

Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation

ORCID Icon, ORCID Icon, ORCID Icon &
Pages 454-462 | Received 23 Nov 2022, Accepted 02 Mar 2023, Published online: 28 Mar 2023

Figures & data

Figure 1. Study design. aA new treatment regimen (gemcitabine + cisplatin) was initially recommended by the National Comprehensive Cancer Network for CCA in 2010. Abbreviations. CCA, cholangiocarcinoma; HPM, health and productivity management.

Figure 1. Study design. aA new treatment regimen (gemcitabine + cisplatin) was initially recommended by the National Comprehensive Cancer Network for CCA in 2010. Abbreviations. CCA, cholangiocarcinoma; HPM, health and productivity management.

Figure 2. Patient cohorts. Patients with evidence of work absence and disability benefits eligibility for analysis in each cohort in patients with CCA, iCCA, and eCCA were full-time employees with ≥1-month post-index enrolment in the HPM and Commercial databases. aPatients with CCA include patients with iCCA, eCCA, or both. In the overall HPM sample, 61 patients had diagnoses for both iCCA and eCCA and were not included in the subsequent iCCA and eCCA cohorts. Abbreviations. CCA, cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma; HPM, health and productivity management; iCCA, intrahepatic cholangiocarcinoma.

Figure 2. Patient cohorts. Patients with evidence of work absence and disability benefits eligibility for analysis in each cohort in patients with CCA, iCCA, and eCCA were full-time employees with ≥1-month post-index enrolment in the HPM and Commercial databases. aPatients with CCA include patients with iCCA, eCCA, or both. In the overall HPM sample, 61 patients had diagnoses for both iCCA and eCCA and were not included in the subsequent iCCA and eCCA cohorts. Abbreviations. CCA, cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma; HPM, health and productivity management; iCCA, intrahepatic cholangiocarcinoma.

Table 1. Baseline demographics and characteristics.

Figure 3. Patients with CCA with one or more absence days during follow-up. (a) Percentage of patients with CCA with one or more absence days during follow-up for any reason or for illness, and (b) the mean number of absence days for illness PPPM. aNot all employers report a specific reason for sick time; reasons included disability, medical leave act, and sick leave. bAmong the subset with one or more absence days for illness (i.e. the mean does not include employees with 0 illness days). Abbreviations. CCA, cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma; iCCA, intrahepatic cholangiocarcinoma; PPPM, per patient per month.

Figure 3. Patients with CCA with one or more absence days during follow-up. (a) Percentage of patients with CCA with one or more absence days during follow-up for any reason or for illness, and (b) the mean number of absence days for illness PPPM. aNot all employers report a specific reason for sick time; reasons included disability, medical leave act, and sick leave. bAmong the subset with one or more absence days for illness (i.e. the mean does not include employees with 0 illness days). Abbreviations. CCA, cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma; iCCA, intrahepatic cholangiocarcinoma; PPPM, per patient per month.

Table 2. Patients with one or more short-term disability or long-term disability claims during follow-up.

Figure 4. Employee productivity costs during follow-up. Abbreviations. CCA, cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma; iCCA, intrahepatic cholangiocarcinoma; PPPM, per patient per month.

Figure 4. Employee productivity costs during follow-up. Abbreviations. CCA, cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma; iCCA, intrahepatic cholangiocarcinoma; PPPM, per patient per month.

Figure 5. Mean all-cause healthcare costs during follow-up. aOutpatient pharmacy services do not include therapies administered in an office setting; infusion therapies administered in an office setting are reflected in the outpatient medical services. Outpatient medical services also include emergency department visits, outpatient office visits, and other outpatient services. Abbreviations. CCA, cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma; iCCA, intrahepatic cholangiocarcinoma; PPPM, per patient per month; SD, standard deviation.

Figure 5. Mean all-cause healthcare costs during follow-up. aOutpatient pharmacy services do not include therapies administered in an office setting; infusion therapies administered in an office setting are reflected in the outpatient medical services. Outpatient medical services also include emergency department visits, outpatient office visits, and other outpatient services. Abbreviations. CCA, cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma; iCCA, intrahepatic cholangiocarcinoma; PPPM, per patient per month; SD, standard deviation.
Supplemental material

Supplemental Material

Download PDF (360.9 KB)

Data availability statement

The data that support the findings of this study are available from Merative. However, restrictions apply to the availability of these data, which were used under license for this study and are not publicly available.